Rivoceranib

Generic Name: Rivoceranib

Drug Type: Small Molecule

Chemical Formula: C_₂₄H_₂₃N_₅O

CAS Number: 811803-05-1

Unique Ingredient Identifier: 5S371K6132

Background: Rivoceranib is under investigation in clinical trial NCT02726854 (Apatinib as Second-line Treatment of Advanced Pancreatic Cancer).

Indication: 本品单药适用于既往至少接受过2种系统化疗后进展或复发的晚期胃腺癌或胃-食管结合部腺癌患者。患者接受治疗时应一般状况良好。

Clinical Trials

Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer.

Phase 2

Completed

Conditions: Biliary Tract Cancer
Anti-PD-1 Therapy
Targeted Molecular Therapy
Capecitabine

Interventions: Drug: Camrelizumab
Drug: apatinib
Drug: Capecitabine

First Posted Date: 2021-01-22

Last Posted Date: 2024-01-30

Lead Sponsor: Beijing Friendship Hospital

Target Recruit Count: 28

Registration Number: NCT04720131

Locations: 🇨🇳
Beijing Friendship Hospital, Beijing, Beijing, China

A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Phase 3

Recruiting

Conditions: Gastric Cancer
HER2 Overexpressing Gastric Carcinoma

Interventions: Drug: RC48-ADC
Drug: Paclitaxel injection
Drug: Irinotecan Hydrochloride Injection
Drug: Apatinib Mesylate Tablets

First Posted Date: 2021-01-19

Last Posted Date: 2023-12-21

Lead Sponsor: RemeGen Co., Ltd.

Target Recruit Count: 351

Registration Number: NCT04714190

Locations: 🇨🇳
Jilin Provincial Tumor Hospital, Changchun, China
🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China

and more 49 locations

Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma

Not Applicable

Completed

Conditions: Effect of Drug
Toxicity, Drug
Secondary Resistance

Interventions: Drug: Apatinib Mesylate
Drug: ifosfamide and etoposide

First Posted Date: 2020-12-30

Last Posted Date: 2022-03-15

Lead Sponsor: Peking University People's Hospital

Target Recruit Count: 79

Registration Number: NCT04690231

Locations: 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China

Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC

Phase 2

Conditions: Small-cell Lung Cancer

Interventions: Drug: camrelizumab
Drug: Apatinib Mesylate
Drug: Carboplatin
Drug: Etoposide

First Posted Date: 2020-12-24

Last Posted Date: 2020-12-24

Lead Sponsor: Chinese Academy of Medical Sciences

Target Recruit Count: 69

Registration Number: NCT04683198

Systemic Chemotherapy, Apatinib Plus Sintilimab for Metastasis ICC

Phase 2

Withdrawn

Conditions: ICC

Interventions: Drug: Systemic Chemotherapy
Drug: Sintilimab
Drug: Apatinib

First Posted Date: 2020-12-23

Last Posted Date: 2021-02-04

Lead Sponsor: Sun Yat-sen University

Registration Number: NCT04682249

Locations: 🇨🇳
Cancer Center Sun Yat-sen University, Guangzhou, Guangdong, China

Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy

Phase 2

Conditions: Advanced Non Squamous NSCLC

Interventions: Drug: Camrelizumab
Drug: Apatinib

First Posted Date: 2020-12-17

Last Posted Date: 2021-06-29

Lead Sponsor: Junling Li

Target Recruit Count: 30

Registration Number: NCT04670913

Locations: 🇨🇳
China, Beijing, Beijing, China

A Study of Fluzoparib Combined With Apatinib as Second-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer（FA-ES-SCLC）

Phase 1

Conditions: Small Cell Lung Cancer Extensive Stage

Interventions: Drug: Fluzoparib
Drug: Apatinib

First Posted Date: 2020-12-09

Last Posted Date: 2020-12-09

Lead Sponsor: Tianjin Medical University Second Hospital

Target Recruit Count: 53

Registration Number: NCT04659785

Locations: 🇨🇳
Tianjin Medical University Second Hospital, Tianjin, Tianjin, China

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer

Phase 2

Completed

Conditions: Cholangiocarcinoma
Biliary Tract Cancer
Biomarker
Hepatobiliary Neoplasm

Interventions: Drug: Apatinib plus Camrelizumab

First Posted Date: 2020-11-24

Last Posted Date: 2021-06-03

Lead Sponsor: Peking Union Medical College Hospital

Target Recruit Count: 22

Registration Number: NCT04642664

Locations: 🇨🇳
Chinese Academy of Medical Sciences & Peking Union Medical College Hospital (CAMS&PUMCH), Beijing, Beijing, China
🇨🇳
Hai-Tao Zhao, Beijing, Beijing, China

A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma (HCC)

Interventions: Drug: Camrelizumab
Drug: Rivoceranib (Apatinib)

First Posted Date: 2020-11-20

Last Posted Date: 2023-04-25

Lead Sponsor: Jiangsu HengRui Medicine Co., Ltd.

Target Recruit Count: 687

Registration Number: NCT04639180

Locations: 🇨🇳
Guangxi Medical University Affiliated Tumor Hospital, Nanjin, Guangzhou, China
🇨🇳
The First Affiliated Hospital of Chongqing Medical University, Chongqing, Chongqing, China
🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China

and more 3 locations

Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer

Phase 2

Conditions: Ovarian Cancer

Interventions: Drug: Apatinib Mesylate
Drug: Abraxane
Drug: Cis Platinum
Drug: Carboplatin

First Posted Date: 2020-10-19

Last Posted Date: 2020-10-19

Lead Sponsor: Zhongshan Hospital Xiamen University

Target Recruit Count: 58

Registration Number: NCT04590625

Locations: 🇨🇳
Zhongshan Hospital Affiliated to Xiamen University, Xiamen, Fujian, China

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy